Pharmacological treatment of obesity in children and adolescents: current status and perspectives

Bibliography

• Daniels SR, Arnett DK, Eckel RH, Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005;111(15):1999-2012
   PubMed Web of Science ®Google Scholar
• Godoy-Matos AF, Guedes EP, Souza LL, Martins MF. Management of obesity in adolescents: state of art. Arq Bras Endocrinol Metabol 2009;53(2):252-61
   PubMedGoogle Scholar
• Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320(7244):1240-3
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Curtin LR, Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010;303(3):242-9
   PubMed Web of Science ®Google Scholar
• Shields M, Tremblay MS. Canadian childhood obesity estimates based on WHO, IOTF and CDC cut-points. Int J Pediatr Obes 2010;5(3):265-73
   PubMed Web of Science ®Google Scholar
• Crocker MK, Yanovski JA. Pediatric obesity: etiology and treatment. Endocrinol Metab Clin North Am 2009;38(3):525-48
   PubMed Web of Science ®Google Scholar
• Barlow SE. Expert committee recommendations regarding the prevention, assessment and treatment of child and adolescents overweight and obesity: summary report. Pediatrics 2007;120(Suppl 4):S164-92
   PubMed Web of Science ®Google Scholar
• Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl 3):S12-23
   Google Scholar
• Carriere F, Renou C, Ransac S, Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001;281:16-28
   PubMed Web of Science ®Google Scholar
• Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39(1):41-6
   PubMed Web of Science ®Google Scholar
• Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60 mg, over-the-counter dosage. Expert Opin Pharmacother 2007;8:1733-42
   PubMed Web of Science ®Google Scholar
• Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs 2010;70(3):335-46
   PubMed Web of Science ®Google Scholar
• Viner RM, Hsia Y, Tomsic T, Wong IC. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev 2009. [Epub ahead of print]
   Google Scholar
• Singhal V, Schwenk WF, Kumar S. Evaluation and management of Childhood and adolescent obesity. Mayo Clin Proc 2007;82(10):1258-64
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Booth SL, Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22(7):814-22
   PubMed Web of Science ®Google Scholar
• Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003;22(5):357-62
   PubMed Web of Science ®Google Scholar
• Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004;163(12):738-41
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Uwaifo GI, Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17(3):307-19
   PubMed Web of Science ®Google Scholar
• Norgren S, Danielsson P, Jurold R, Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003;92(6):666-70
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C, Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293(23):2873-83
   PubMed Web of Science ®Google Scholar
• Maahs D, de Serna DG, Kolotkin RL, Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006;12(1):18-28
   PubMedGoogle Scholar
• Fabricatore AN, Wadden TA, Moore RH, Attrition from Randomized Controlled Trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10(3):333-41
   PubMed Web of Science ®Google Scholar
• Fujita Y, Hosokawa M, Fujimoto S, Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice. Diabetologia 2010;53(7):1472-81
   PubMed Web of Science ®Google Scholar
• Hou X, Song J, Li XN, Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 2010;396(2):199-205
   PubMed Web of Science ®Google Scholar
• Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009;116(8):607-20
   PubMed Web of Science ®Google Scholar
• Foss MT, Clement KD. Metformin as a cause of late-onset chronic diarrhea. Pharmacotherapy 2001;21(11):1422-24
   PubMed Web of Science ®Google Scholar
• Chau-Van C, Gamba M, Salvi R, Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007;148(2):507-11
   PubMed Web of Science ®Google Scholar
• Romualdi D, De Marinis L, Campagna G, Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clin Endocrinol (Oxf) 2008;69(4):562-7
   PubMed Web of Science ®Google Scholar
• Aubert G, Mansuy V, Voirol MJ, The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism 2010. [Epub ahead of print]
   Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30(5):359-71
   PubMed Web of Science ®Google Scholar
• Kay JP, Alemzadeh R, Langley G, Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50(12):1457-61
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ambler GR, Baur LA, Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91(6):2074-80
   PubMed Web of Science ®Google Scholar
• Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2008;21(4):339-48
   PubMed Web of Science ®Google Scholar
• Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008;152(6):817-22
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163(12):2072-9
   PubMed Web of Science ®Google Scholar
• Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord 2001;25(Suppl 4):S8-11
   PubMedGoogle Scholar
• Ledonne A, Sebastianelli L, Federici M, The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells. Br J Pharmacol 2009;156(6):962-9
   PubMed Web of Science ®Google Scholar
• Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord 2002;26(9):1245-53
   PubMed Web of Science ®Google Scholar
• Berkowitz RI, Fujioka K, Daniels SR, ; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145(2):81-90
   PubMed Web of Science ®Google Scholar
• Ryan DH. Clinical use of sibutramine. Drugs Today (Barc) 2004;40(1):41-54
   PubMed Web of Science ®Google Scholar
• Reisler G, Tauber T, Afriat R, Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006;8(1):30-2
   PubMed Web of Science ®Google Scholar
• Garcia-Morales LM, Berber A, Macias-Lara CC, Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006;28(5):770-82
   PubMed Web of Science ®Google Scholar
• Godoy-Matos A, Carraro L, Vieira A, Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. Clin Endocrinol Metab 2005;90(3):1460-65
   Google Scholar
• Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289(14):1805-12
   PubMed Web of Science ®Google Scholar
• Daniels SR, Long B, Crow S, ; Sibutramine Adolescent Study Group. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007;120(1):147-57
   Web of Science ®Google Scholar
• Alterio V, Monti SM, Truppo E, The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex. Org Biomol Chem 2010. [Epub ahead of print]
   Google Scholar
• Ghanizadeh A. Loss of taste and smell during treatment with topiramate. Eat Weight Disord 2009;14(2-3):137-8
   Web of Science ®Google Scholar
• Li HF, Zou Y, Xia ZZ, Effects of topiramate on weight and metabolism in children with epilepsy. Acta Paediatr 2009;98(9):1521-5
   PubMed Web of Science ®Google Scholar
• Fernandez-Mayoralas DM, Fernandez-Jaen A, Jareno NM, Meralgia paresthetica in the pediatric population: a propos of 2 cases. J Child Neurol 2010;25(1):110-13
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. Diab Sci Technol 2008;2(5):913-18
   PubMedGoogle Scholar
• Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem 2008;23(2):271-6
   PubMed Web of Science ®Google Scholar
• Anderson JW, Greenway FL, Fujioka K, Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10(7):633-41
   PubMedGoogle Scholar
• Thomsen WJ, Grottick AJ, Menzaghi F, Lorcaserin, a novel selective human 5-HT2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325(2):577-87
   PubMed Web of Science ®Google Scholar
• Kopelman P, Bryson A, Hickling R, Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007;31(3):494-9
   PubMed Web of Science ®Google Scholar
• Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res 2007;62(6):746-9
   PubMed Web of Science ®Google Scholar
• Stoeckel LE, Weller RE, Giddings M, Cox JE. Peptide YY levels are associated with appetite suppression in response to long-chain fatty acids. Physiol Behav 2008;93(1-2):289-95
   PubMed Web of Science ®Google Scholar
• Suzuki K, Simpson KA, Minnion JS, The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010;57(5):359-72
   PubMed Web of Science ®Google Scholar